Time of onset of action of acrivastine in the skin of pollen-allergic subjects. A double-blind, randomized, placebo-controlled comparative study.
The purpose of this study was to assess the time of onset of action of acrivastine in suppressing the wheal response to histamine (10 mg/ml) and allergen (10,000 and 100,000 BU/ml) in the skin prick test. Ten subjects with a well-documented allergy to pollen received single doses of 8 mg of acrivastine and placebo according to a randomized, double-blind, placebo-controlled, crossover treatment design. Duplicate skin prick tests were performed 0, 15, 20, 25, 30, and 60 min after medication. The results demonstrated a statistically significant suppression of the wheal reactions 15-20 min after medication, depending on the reaction producers used. The sum of all three producers showed a statistically significant effect on the wheal reaction 15 min after medication. The upper 95% confidence limit for time lag from dosing of acrivastine until reduction from placebo level commences was 6.5 min. The study substantiates that orally administered acrivastine has a rapid onset of action in the skin of allergic subjects. The results indicate that allergen SPT is a more sensitive tool for studying antihistaminergic activity than histamine SPT.
Petersen
L J
LJ
Department of Medicine TTA, National University Hospital, Copenhagen, Denmark.
Bindslev-Jensen
C
C
Poulsen
L K
LK
Malling
H J
HJ
D000284:Administration, Oral; D000328:Adult; D000485:Allergens; D016001:Confidence Intervals; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000276:immunology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011058:Pollen; D012882:Skin Tests; D013997:Time Factors; D014311:Triprolidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
D000485:Allergens; D006634:Histamine H1 Antagonists; D014311:Triprolidine; D006632:Histamine; C043648:acrivastine